Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.…
Vera Therapeutics Inc (VERA) (Q3 2026) Earnings Call Highlights: TRUTAKNA Launch Off to a ...
Vera Therapeutics (NASDAQ: VERA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 362 employees.
The shares were at 25.45 USD on 20 November 2026, up 0.9% over 52 weeks. Its 52-week range is 23.86 USD to 56.05 USD: the price is 54.6% below the high and 6.7% above the low.
Its market capitalisation is 1.84B USD.
Vera Therapeutics reports return on equity of -49.6%.
It holds more cash than debt, a net cash position of 307.25M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 71.36 USD is 180.4% above the current price. The next earnings report is expected on 25 February 2027.